ALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024.

ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September.

ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2024.

ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

ALISO VIEJO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Truist Securities MedTech Conference.

ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to purchase up to 267,857 additional shares. RxSight’s gross proceeds from the offering were $115.0 million, before deducting underwriting discounts and commissions and other offering expenses.

ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by RxSight. Before deducting the underwriting discount and estimated offering expenses payable by RxSight, RxSight expects to receive gross proceeds of approximately $100.0 million, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 13, 2024, subject to satisfaction of customary closing conditions. BofA Securities is acting as lead bookrunning manager of the offering and as representative of the underwriters. J.P. Morgan is also acting as bookrunning manager for the offering. BTIG is acting as co-manager of the offering.

ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering on the same terms and conditions. RxSight intends to use the net proceeds from the offering for continued commercial and marketing expansion, including international expansion, funding of product development, research and clinical development, and for working capital and general corporate purposes. All of the shares are being offered by RxSight. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. BofA Securities is acting as lead bookrunning manager of the offering and as representative of the underwriters.  J.P. Morgan is also acting as bookrunning manager and BTIG is acting as a co-manager of the offering.

ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024.

ALISO VIEJO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference.

ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

ALISO VIEJO, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.

ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference.

ALISO VIEJO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 34th Annual Oppenheimer Healthcare Conference.

ALISO VIEJO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended December 31, 2023.

ALISO VIEJO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Wednesday, February 28, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Insiders are selling these hot stocks and may cap gains in the near term, but long-term gains are in the outlook. Analysts support them and raise their targets.

ALISO VIEJO, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2023 and provided full-year 2024 guidance.

ALISO VIEJO, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.

ALISO VIEJO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and nine months ended September 30, 2023.

ALISO VIEJO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- November 2, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced educational opportunities and product updates at the American Academy of Ophthalmology (AAO) Annual Meeting on November 3 – 6 in San Francisco. These include three scientific poster presentations (PO005, PO457, PO050) and 15 booth presentations (booth #229). At these events, leading U.S.-based ophthalmologists are slated to discuss diverse topics, including maximizing clinical results using the Light Adjustable Lens™ (LAL®) across a broad range of patient profiles, integration of the adjustable lens workflow, and real-life case studies showing the impact of high-quality, customized LAL vision. For the full program of events taking place at AAO 2023, click here.

ALISO VIEJO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter 2023 after the market close on Thursday, November 9, 2023. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

ALISO VIEJO, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Wells Fargo Healthcare Conference.

ALISO VIEJO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2023.